Three‐dose–cohort designs in cancer phase I trials
Authors:
- 31 August 2007
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 27 (12) , 2070-2093
Abstract
Traditional designs for phase I clinical trials assign the same dose to patients in the same cohort. In this paper, we present a new class of designs for cancer phase I trials which initially rapidly escalate by allowing multiple doses (usually 3) to be assigned to each cohort of patients. The class of designs, called the LMH-CRM (an extension of the continual reassessment method (CRM) by administering different percentiles of the maximum tolerated dose (MTD), denoted ‘low’, ‘medium’, ‘high’), is proven to be consistent and coherent (a commonsense property of phase I trials for dose escalation and de-escalation). Three designs (slow, moderate and fast) are derived based on different dose-escalation restrictions. Simulation results show that moderate and fast LMH-CRM combine the advantages of the CRM with one patient per cohort and three patients per cohort: it accurately estimates the MTD; controls overall toxicity rates; and is time efficient. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Coherence principles in dose-finding studiesBiometrika, 2005
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment MethodBiometrics, 2002
- Continual Reassessment Method: A Likelihood Approach1996
- Consistency of continual reassessment method under model misspecificationBiometrika, 1996
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- Practical modifications of the continual reassessment method for phase i cancer clinical trialsJournal of Biopharmaceutical Statistics, 1994
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993
- How can we find an optimal dose?Toxicology and Applied Pharmacology, 1965